WO2016178099A1 - Nano floro tricyclohexane - Google Patents

Nano floro tricyclohexane Download PDF

Info

Publication number
WO2016178099A1
WO2016178099A1 PCT/IB2016/050016 IB2016050016W WO2016178099A1 WO 2016178099 A1 WO2016178099 A1 WO 2016178099A1 IB 2016050016 W IB2016050016 W IB 2016050016W WO 2016178099 A1 WO2016178099 A1 WO 2016178099A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
new drug
drug molecule
tyrosyl
dna phosphodiesterase
Prior art date
Application number
PCT/IB2016/050016
Other languages
French (fr)
Inventor
Mustafa Pehlivan
Original Assignee
Mustafa Pehlivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mustafa Pehlivan filed Critical Mustafa Pehlivan
Priority to PCT/IB2016/050016 priority Critical patent/WO2016178099A1/en
Publication of WO2016178099A1 publication Critical patent/WO2016178099A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • Tyrosyl DNA Phosphodiesterase 1 Inhibition of Tyrosyl DNA Phosphodiesterase 1 is involved in the repairement of cancer as it repairs irreversible top-1 DNA covalent complexes [1 ]. Tyrosyl DNA Phosphodiesterase 1 inhibition can also be beneficial for treating malignant glioma, as identified by Al-Keilani [2]. The aims of this study were to establish a way to computationally predict how this enzyme can be inhibited with a certain novel new drug molecule designed on computer to see what enzymatic activity it may have for specifically and inhibiting only Tyrosyl DNA Phosphodiesterase 1 .
  • Figure 1 shows the organic structure of the new drug molecule (Nano-floro- tricyclohexane) and Figure 2 shows the enzymatic activity and inhibition efficacy of the new novel drug compound, whereas figure 3 provides ADME (Absorption, Distribution, Metabolism, Elimination) data of this compound.
  • ADME Absorption, Distribution, Metabolism, Elimination
  • Tyrosyl DNA Phosphodiesterase as an anticancer therapy, Anticancer Agents Med Chem. 2008 May; 8(4): 381 -389 Role of Tyrosyl-DNA Phosphodiesterase I (TDP1 ) as a Prognostic and Predictiv Factor in Malignant Glioma, Al-Keilani (Iowa Research 2013) http://www.swisstargetprediction.ch/ http://lmmd.ecust.edu.cn:8000/ Johan W.M. Heemskerk et al., Platelet Activation and Blood Coagulation, Thromb haemost 2002, 88; 186-93

Abstract

This invention is about the discovery of a new drug molecule that will inhibit the enzyme Tyrosyl DNA Phosphodiesterase 1. Tyrosyl DNA Phosphodiesterase 1 is a very important enzyme in terms of metastatic cancer treatment as it is involved in repairing damaged DNA of cancer cells. When Cancer cells (tumors) are damaged by Chemotherapeutic anti cancer drugs, tyrosyl DNA Phosphodiesterase 1 is activated and repairs damaged cancer cells. As a result, cancer continues spreading within the body. If Tyrosyl DNA Phosphodiesterase 1 could be stopped doing that, cancer would stop spreading and therefore the cancer Chemotherapy drugs will provide much better therapeutic effects that will lead to stopping cancer. For this reason, targeting Tyrosyl DNA Phosphodiesterase 1 has always been a target for Scientists who work on the discovery of new drug molecules. The purpose of this study is to introduce such a new drug molecule with in silico computational results with the relevant data. The compound is 1,8,8-trifluoro,1-trifluoromethyl,4a- (1,4,4-trifluorocyclohexyl)decalin.

Description

NANO FLORO TRICYCLOHEXANE
NEW DRUG DISCOVERY (NANO-FLORO-TRICYCLOHEXANE) THAT WILL
BREAK THE RESISTANCE MECHANISM OF CANCER
Inhibition of Tyrosyl DNA Phosphodiesterase 1 is involved in the repairement of cancer as it repairs irreversible top-1 DNA covalent complexes [1 ]. Tyrosyl DNA Phosphodiesterase 1 inhibition can also be beneficial for treating malignant glioma, as identified by Al-Keilani [2]. The aims of this study were to establish a way to computationally predict how this enzyme can be inhibited with a certain novel new drug molecule designed on computer to see what enzymatic activity it may have for specifically and inhibiting only Tyrosyl DNA Phosphodiesterase 1 . The online software called "Swiss target predictor" [3] was then used to find such novel molecules, and in one of the trials, such a novel compound that has 95% inhibition efficacy against tyrosyl DNA Phosphodiesterase 1 has been discovered. The molecule was Nano Floro tricyclohexane and figure 1 shows the open formula fort his novel drug molecule along with its inhibition data. The open chemical formula (SMILES) of this molecule was then entered into the ADMET predictor software online to see what Pharmacokinetic effects it may have [4]. The result was that it was a partial inhibitor of glycoproteins which are responsible from clotting [5] No other potential side effects were shown.
Figure 1 shows the organic structure of the new drug molecule (Nano-floro- tricyclohexane) and Figure 2 shows the enzymatic activity and inhibition efficacy of the new novel drug compound, whereas figure 3 provides ADME (Absorption, Distribution, Metabolism, Elimination) data of this compound.
It is evidenced within this study that a novel effective new drug molecule has been discovered that would treat and cure cancer. In future, it is expected that this drug molecule could be synthesized and then enters clinical trials. It is also expected that this active drug, if successful by the end of clinical trials, should be given to patients suffering from cancer with moderate to high dose vitamin K to prevent inner bleeding as the molecule has potential of inhibiting glycoproteins that may result in thinning blood. References:
Thomas S. Dexheimer et al. , Tyrosyl DNA Phosphodiesterase as an anticancer therapy, Anticancer Agents Med Chem. 2008 May; 8(4): 381 -389 Role of Tyrosyl-DNA Phosphodiesterase I (TDP1 ) as a Prognostic and Predictiv Factor in Malignant Glioma, Al-Keilani (Iowa Research 2013) http://www.swisstargetprediction.ch/ http://lmmd.ecust.edu.cn:8000/ Johan W.M. Heemskerk et al., Platelet Activation and Blood Coagulation, Thromb haemost 2002, 88; 186-93

Claims

Claims
1 . This invention is a new drug molecule (Nano-floro-tricyclohexane) computationaly predicted to stop cancer from spreading.
2. The drug molecule is shown to highly and specifically inhibit the enzyme Tyrosyl DNA Phosphodiesterase 1 , the enzyme that repairs damaged DNA of cancer cells, according to claim 1 .
3. Two figures related to this new drug molecule (Nano-floro-tricyclohexane) have been provided, the former shows the efficacy and enzymatic inhibition levels of the new drug molecule, and the latter shows the Pharmacokinetic ADME (how the drug will be absorbed and work within the body) properties, based on claim 1 .
4. This new drug molecule is the first in its own category as there are no other Tyrosyl DNA Phosphodiesterase 1 inhibitors in the market.
5. Once synthesized and clinically tried, this new drug, according to claim 1 , will stop metastatis (spreading cancer) and in combination with other anti cancer (Chemotherapy) drug(s), it will provide rapid healing as the damaged DNA of cancer cells will not be repaired anymore, due to the inhibition of the enzyme human Tyrosyl DNA Phosphodiesterase 1 . Therefore, synthesis and initiation of clinical trials in relation to this new drug molecule will be highly beneficial in terms of patients suffering from cancer.
PCT/IB2016/050016 2016-01-04 2016-01-04 Nano floro tricyclohexane WO2016178099A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2016/050016 WO2016178099A1 (en) 2016-01-04 2016-01-04 Nano floro tricyclohexane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2016/050016 WO2016178099A1 (en) 2016-01-04 2016-01-04 Nano floro tricyclohexane

Publications (1)

Publication Number Publication Date
WO2016178099A1 true WO2016178099A1 (en) 2016-11-10

Family

ID=55275126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/050016 WO2016178099A1 (en) 2016-01-04 2016-01-04 Nano floro tricyclohexane

Country Status (1)

Country Link
WO (1) WO2016178099A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111812315A (en) * 2019-04-12 2020-10-23 中国科学院化学研究所 Drug damage DNA functionalized magnetic nano affinity probe and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253529A1 (en) * 1986-06-24 1988-01-20 Isc Chemicals Limited Fluorinated polycyclic compounds
JPH0256462A (en) * 1988-08-19 1990-02-26 Asahi Glass Co Ltd Retinoid analog and production thereof
WO1996000568A1 (en) * 1994-06-29 1996-01-11 Igor Vyacheslavovich Belov Anti-metastatic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253529A1 (en) * 1986-06-24 1988-01-20 Isc Chemicals Limited Fluorinated polycyclic compounds
JPH0256462A (en) * 1988-08-19 1990-02-26 Asahi Glass Co Ltd Retinoid analog and production thereof
WO1996000568A1 (en) * 1994-06-29 1996-01-11 Igor Vyacheslavovich Belov Anti-metastatic agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AI-KEILANI: "Role of Tyrosyl-DNA Phosphodiesterase I (TDP1) as a Prognostic and Predictiv Factor in Malignant Glioma", IOWA RESEARCH, 2013
C. MARCHAND ET AL: "Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay", MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 1, 1 January 2009 (2009-01-01), US, pages 240 - 248, XP055297734, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-08-0878 *
JOHAN W.M. HEEMSKERK ET AL.: "Platelet Activation and Blood Coagulation", THROMB HAEMOST, vol. 88, 2002, pages 186 - 193
THOMAS S. DEXHEIMER ET AL.: "Tyrosyl DNA Phosphodiesterase as an anticancer therapy", ANTICANCER AGENTS MED CHEM., vol. 8, no. 4, May 2008 (2008-05-01), pages 381 - 389

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111812315A (en) * 2019-04-12 2020-10-23 中国科学院化学研究所 Drug damage DNA functionalized magnetic nano affinity probe and preparation method and application thereof

Similar Documents

Publication Publication Date Title
Ashrafizadeh et al. Autophagy, anoikis, ferroptosis, necroptosis, and endoplasmic reticulum stress: Potential applications in melanoma therapy
Malik et al. Role of natural radiosensitizers and cancer cell radioresistance: an update
Taylor et al. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma
Kumar et al. Drug targets for cancer treatment: an overview
Wei et al. Novel insights into the roles of Rho kinase in cancer
BR112014016163A8 (en) fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
NO20050528L (en) Combination of VEGF receptor tyrosine kinase inhibitors for the treatment of cancer
He et al. Emerging roles of lncRNAs in the formation and progression of colorectal cancer
Gao et al. Autophagy and tumour radiotherapy
Hwang et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
DE602006020621D1 (en) COMBINATION OF ZD6474 AND PEMETREXED
Yuan et al. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
Kamran et al. Applying precision oncology principles in radiation oncology
CY1111482T1 (en) COMBINATION AZD2171 AND PERMETRAXED
Giuliani et al. Autophagy and cancer: taking the ‘toxic’out of cytotoxics
BR112018076821A2 (en) phthalazine derivatives as parp1, parp2 and / or tubulin inhibitors useful for cancer treatment
Wang et al. RETRACTED: Overexpression of FADD and Caspase-8 inhibits proliferation and promotes apoptosis of human glioblastoma cells
Hong et al. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation
AU2007219572B2 (en) Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
Li et al. Cross‑link between ferroptosis and nasopharyngeal carcinoma: New approach to radiotherapy sensitization
WO2016178099A1 (en) Nano floro tricyclohexane
Huang et al. Is extremely low frequency pulsed electromagnetic fields applicable to gliomas? A literature review of the underlying mechanisms and application of extremely low frequency pulsed electromagnetic fields
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
Zheng et al. Targeting Cullin-RING E3 ligases for radiosensitization: from NEDDylation inhibition to PROTACs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16702584

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16702584

Country of ref document: EP

Kind code of ref document: A1